ProCE Banner Activity

Venetoclax Active in Relapsed/Refractory CLL After Treatment With Ibrutinib or Idelalisib

Slideset Download
Conference Coverage
Phase II data demonstrate that venetoclax monotherapy is active in patients with R/R CLL and prior treatment with either ibrutinib or idelalisib, including those with refractory disease.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals